Accueil>>Signaling Pathways>> Proteases>> ACE>>Quinapril HCl

Quinapril HCl (Synonyms: CI-906, PD 109452-2)

Catalog No.GC12368

Le quinapril (chlorhydrate) (CI-906) est un promédicament qui appartient À la classe des inhibiteurs de l'enzyme de conversion de l'angiotensine (ECA).

Products are for research use only. Not for human use. We do not sell to patients.

Quinapril HCl Chemical Structure

Cas No.: 82586-55-8

Taille Prix Stock Qté
10mM (in 1mL DMSO)
38,00 $US
En stock
50mg
49,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Quinapril (hydrochloride) (CI-906) is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications.

Quinapril (hydrochloride) (CI-906) is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure. Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor[1][2].

References:
[1]. Song, J.C. and C.M. White, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet, 2002. 41(3): p. 207-24.
[2]. Culy, C.R. and B. Jarvis, Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs, 2002. 62(2): p. 339-85.

Avis

Review for Quinapril HCl

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Quinapril HCl

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.